Respect Poonawala should be an announcement to run for India’s pharmaceutical prowess. Instead, the billionaire owner and chief executive of the world’s largest vaccine maker, Pune-based Serum, has become a symbol of India’s close ties with the private sector.
Before Covid-19, there was no serum house name even within the country. Now the unlisted company has India’s best hope of coming out of its Covid-19 crisis. 392,488 new cases in the last 24 hours; In the state of Goa, 40% of the tests are returning positive. The manufacturer’s monthly production is the production of 70 million doses of Covishield, the local name for the AstraZeneca vaccine, which is about 60% dosed.
He complains to the company’s founding son, 40-year-old Mr. Poonawala, particularly distressing. In an interview with the Times newspaper, he claimed that tycoons and politicians were pushing him to punch him. A few days before the Times interview was published on Saturday, India had given security protection to Mr Poonawala, in which he said he wanted to stay in London longer due to pressure. He then suggested that he return in a few days.
At the root of the problem is New Delhi’s vaccine procurement strategy. India decided in April to allow state governments and private hospitals to buy up to half a share of the vaccine, although under the new scheme they could pay twice or more as paid by the government. It effectively shuts down the unreliable obligation of private companies to ration a limited supply of life-saving vaccines. If the government will distribute centrally.
Politicians in some of the richest countries placed initial orders for more jobs than they needed, giving producers greater confidence in increasing production. Prime Minister Narendra Modi’s administration gave the order slowly and only after the vaccines were approved. Now India’s attempt to accelerate its vaccination drive will come at another cost. For example, COVX, supported by the World Health Organization. The facility is also counting serums to supply where cases are increasing in low-income countries. Those export deals are now halted.
Mr. Poonawala has not helped his image by describing small profit margins as philanthropy. But the man accused of saving Indian lives lives in danger, and plans further expansion abroad. It is a terrible sight for India.